Content

• Pharmacy Retail (And Healthcare Supply Chain) — India Sector Deep-Dive
• A. Industry Overview & Market Landscape
• 1) What The “Sector” Includes In Practice
• 2) Market Size And Industry Structure (Quantitative Points Disclosed)
• 3) Consolidation Trajectory (Distribution Layer)
• 4) Retail Chain Footprint And Competitive Context (Front-End Layer)
• 5) Omni-Channel And Consumer Proposition (Retail Layer)
• B. Financial & Economic Profile
• 1) Revenue Scale And Growth (Company Evidence As Sector Proxy)
• 2) Profitability Levels And Margin Ranges (What “Good” Looks Like Here)
• 3) Returns And Capital Efficiency
• 4) Working Capital And Cash Conversion: Structural Constraint And Differentiator
• C. Competitive Structure & Dynamics
• 1) Concentration And Market Share Realities
• 2) Competitive Moats And Differentiation (As Evidenced By The Two Models)
• 3) Porter'S 5 Forces-Style Intensity Snapshot (Grounded In Disclosed Dynamics)
• 4) M&A And Consolidation As A Core Competitive Weapon (Distribution)
• D. Operational Characteristics
• 1) Retail Operations (Medplus): Store Cohorts, Omni-Channel, And Inventory Physics
• 2) Distribution Operations (Entero): Footprint, Sku Breadth, And Working Capital Control
• E. Growth Dynamics & Drivers
• 1) Retail Growth (Medplus): Expansion + Maturation + Mix
• 2) Distribution Growth (Entero): Consolidation + Organic Outperformance + Medtech Mix
• F. Risk Landscape
• 1) Industry-Wide Risks (Systemic Across Retail And Distribution)
• 2) Retail-Specific Risks (Medplus)
• 3) Distribution-Specific Risks (Entero)
• G. Capital Allocation & Investor Returns
• 1) Retail: Capex, Leases, And Store-Driven Reinvestment (Medplus)
• 2) Distribution: Acquisition-Led Capital Allocation And Working-Capital Funding (Entero)
• H. Future Outlook & Projections (As Disclosed)
• 1) Medplus (Retail): “No Guidance” But Directional Targets Disclosed
• 2) Entero (Distribution): Explicit Fy27 Guidance
• I. Company-By-Company Profiles
• 1) Medplus Health Services Limited (Nse: Medplus | Bse: 543427)
• Business Description And Positioning
• Scale And Footprint
• Fy26 Financial Performance (Consolidated)
• Q4fy26 Snapshot (Consolidated)
• Segment Economics (Fy26 And Q4fy26)
• Ind As Lease Accounting Effects (Reported Vs Adjusted)
• Store Network Changes And Closures (Q4fy26)
• Working Capital And Balance Sheet (Selected, ₹M)
• Strategy And Priorities (As Disclosed)
• Notable Watch-Items
• 2) Entero Healthcare Solutions Limited (Nse: Entero | Bse: 544122)
• Business Description And Positioning
• Scale And Footprint
• Fy26 Financial Performance (Consolidated)
• Q4fy26 Snapshot
• Fy27 Guidance (Explicit)
• Strategy And Priorities
• Balance Sheet Highlights (Mar-26 Vs Mar-25; Rs. Cr)
• Notable Watch-Items
• Cross-Company Synthesis: What The Combined Evidence Says About The Sector
• 1) Organized Penetration Is Still Tiny, But Scaling Is Real
• 2) The “Playbook” Is Shifting From Pure Expansion To Quality Of Growth
• 3) Mix Is The Durable Margin Lever In Both Business Models
• 4) Working Capital Is The “Hidden Battlefield”
• 5) Unit Economics Vs Consolidated Economics: Maturity Matters
• Appendix-Style Numeric Compendium Embedded In Narrative (Selected High-Signal Items)
• Medplus — Selected Operational And Financial Numeric Details
• Entero — Selected Operational And Financial Numeric Details